-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Transurethral prostatectomy (TURP) is the surgical treatment of
The value of benign TURP to rule out prostate cancer remains controversial
The aim of this study was to study prostate cancer incidence and mortality risk
Between 1995 and 2016, a total of 63,781 individuals with at least one TURP were found in DAPCaR, of which 42,558 men had no history of prostate TURP pre-biopsy and a benign histopathological history of initial TURP (Figure 1
Figure 2 depicts the initial TURP performed each year in Denmark and the rough number
A total of 6685 men underwent follow-up histological examinations
The median follow-up of event-free men was 15 years after benign initial TURP (IQR, 10-19 years), and a total of 8513 men were followed for more than 15 years
Men with low PSA levels and benign TURP can be assured of their cancer risk and do not need to be monitored
Original source:
Hilscher M, Røder A, Helgstrand JT, Klemann N, Brasso K, Vickers AJ, Stroomberg HV.